{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:49:33Z","timestamp":1789760973550,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00228-025-03913-8","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:42:34Z","timestamp":1757450554000},"page":"1759-1772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of fondaparinux use in hemodialysis patients with heparin-induced thrombocytopenia: a systematic review"],"prefix":"10.1007","volume":"81","author":[{"given":"Milorad","family":"Stojadinovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6305-5485","authenticated-orcid":false,"given":"Radica","family":"Zivkovic-Zaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Baralic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Jovicic-Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bontic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemanja","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pejcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"Suppl 4","key":"3913_CR1","doi-asserted-by":"publisher","first-page":"i45","DOI":"10.1093\/ckj\/sfab198","volume":"14","author":"B Canaud","year":"2021","unstructured":"Canaud B, Stuard S, Laukhuf F, Yan G, Canabal MIG, Lim PS et al (2021) Choices in hemodialysis therapies: variants, personalized therapy and application of evidence-based medicine. Clin Kidney J 14(Suppl 4):i45-58","journal-title":"Clin Kidney J"},{"issue":"2","key":"3913_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/ckj\/sfx009","volume":"10","author":"NGL Jager","year":"2017","unstructured":"Jager NGL, Zandvliet AS, Touw DJ, Penne EL (2017) Optimization of anti-infective dosing regimens during online haemodiafiltration. Clin Kidney J 10(2):282\u2013290","journal-title":"Clin Kidney J"},{"key":"3913_CR3","first-page":"11","volume":"29","author":"L Li","year":"2020","unstructured":"Li L, Li X, Xia Y, Chu Y, Zhong H, Li J et al (2020) Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Front Pharmacol 29:11","journal-title":"Front Pharmacol"},{"issue":"4","key":"3913_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.14740\/jh876","volume":"10","author":"J Kaur","year":"2021","unstructured":"Kaur J, Arsene C, Yadav SK, Ogundipe O, Malik A, Sule AA et al (2021) Risk factors in hospitalized patients for heparin-induced thrombocytopenia by real world database: a new role for primary hypercoagulable states. J Hematol 10(4):171\u2013177","journal-title":"J Hematol"},{"key":"3913_CR5","doi-asserted-by":"crossref","unstructured":"Ng JY, D\u2019Souza M, Hutani F, Choi P. Management of heparin-induced thrombocytopenia: a contemporary review. J Clin Med. 2024 Aug 9;13(16).","DOI":"10.3390\/jcm13164686"},{"issue":"6","key":"3913_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood.2024027599","volume":"145","author":"PYI Choi","year":"2025","unstructured":"Choi PYI, Mitchell I (2025F 6) Antibodies to PF4 in severe COVID-19: same but different. Blood 145(6):559\u2013560","journal-title":"Blood"},{"key":"3913_CR7","unstructured":"Nicolas D, Nicolas S, Hodgens A, Reed M. Heparin-induced thrombocytopenia. In: StatPearls [Internet], editor. Treasure Island (FL): StatPearls Publishing; 2025."},{"issue":"983","key":"3913_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","volume":"83","author":"I Ahmed","year":"2007","unstructured":"Ahmed I, Majeed A, Powell R (2007) Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J 83(983):575\u2013582","journal-title":"Postgrad Med J"},{"issue":"29","key":"3913_CR9","first-page":"107602962311779","volume":"30","author":"R Hamadi","year":"2023","unstructured":"Hamadi R, Sakr F, Aridi H, Alameddine Z, Dimachkie R, Assaad M et al (2023) Heparin-induced thrombocytopenia in chronic hemodialysis patients. Clin Appl Thromb Hemost 30(29):107602962311779","journal-title":"Clin Appl Thromb Hemost"},{"issue":"21","key":"3913_CR10","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.jacc.2017.09.1099","volume":"70","author":"M Schindewolf","year":"2017","unstructured":"Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J et al (2017) Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia. J Am Coll Cardiol 70(21):2636\u20132648","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3913_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863X19898253","volume":"25","author":"M Hogan","year":"2020","unstructured":"Hogan M, Berger JS (2020) Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med 25(2):160\u2013173","journal-title":"Vasc Med"},{"issue":"5","key":"3913_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.nefro.2018.02.010","volume":"38","author":"J Gameiro","year":"2018","unstructured":"Gameiro J, Jorge S, Lopes JA (2018) Haemodialysis-related-heparin-induced thrombocytopenia: case series and literature review. Nefrologia 38(5):551\u2013557","journal-title":"Nefrologia"},{"issue":"20","key":"3913_CR13","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1182\/blood-2012-07-443051","volume":"120","author":"A Cuker","year":"2012","unstructured":"Cuker A, Gimotty PA, Crowther MA, Warkentin TE (2012) Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 120(20):4160\u20134167","journal-title":"Blood"},{"key":"3913_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.thromres.2019.11.004","volume":"185","author":"J Brodard","year":"2020","unstructured":"Brodard J, Alberio L, Angelillo-Scherrer A, Nagler M (2020) Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Res 185:27\u201330","journal-title":"Thromb Res"},{"issue":"1","key":"3913_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","volume":"67","author":"D Sheridan","year":"1986","unstructured":"Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67(1):27\u201330","journal-title":"Blood"},{"issue":"22","key":"3913_CR16","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","volume":"2","author":"A Cuker","year":"2018","unstructured":"Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2(22):3360\u20133392","journal-title":"Blood Adv"},{"key":"3913_CR17","doi-asserted-by":"crossref","unstructured":"Bauersachs RM, Lindhoff-Last E, Klamroth R, Koster A, Schindewolf M, Magnani H. Danaparoid-consensus recommendations on its clinical use. Pharmaceuticals (Basel). 2024 Nov 25;17(12).","DOI":"10.3390\/ph17121584"},{"issue":"1","key":"3913_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","volume":"109","author":"MM Samama","year":"2003","unstructured":"Samama MM, Gerotziafas GT (2003) Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 109(1):1\u201311","journal-title":"Thromb Res"},{"issue":"1","key":"3913_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-023-00643-4","volume":"24","author":"D Ghaziri","year":"2023","unstructured":"Ghaziri D, Dehaini H, Msheik M, Bahmad M, Zorkot M, Saad GA (2023) Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol. BMC Pharmacol Toxicol 24(1)","journal-title":"BMC Pharmacol Toxicol"},{"key":"3913_CR20","doi-asserted-by":"crossref","unstructured":"Li JF, Wu LJ, Wen GY, Zhou RR, liu F, Wang W, et al. Platelet count trends and response to fondaparinux in a cohort of heparin-induced thrombocytopenia suspected patients after pulmonary endarterectomy. J Thromb Thrombolysis. 2021 Apr 7;51(3):703\u201310.","DOI":"10.1007\/s11239-020-02260-y"},{"issue":"5","key":"3913_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1586\/ehm.10.54","volume":"3","author":"TE Warkentin","year":"2010","unstructured":"Warkentin TE (2010) Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 3(5):567\u2013581","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"3913_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020367","volume":"12","author":"R Zivkovic Zaric","year":"2023","unstructured":"Zivkovic Zaric R, Zaric M, Sekulic M, Zornic N, Nesic J, Rosic V et al (2023) Antimicrobial treatment of Serratia marcescens invasive infections: systematic review. Antibiotics 12(2)","journal-title":"Antibiotics"},{"issue":"4","key":"3913_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijmmb.2021.06.005","volume":"39","author":"RZ Zaric","year":"2021","unstructured":"Zaric RZ, Jankovic S, Zaric M, Milosavljevic M, Stojadinovic M, Pejcic A (2021) Antimicrobial treatment of Morganella morganii invasive infections: systematic review. Indian J Med Microbiol 39(4):404\u2013412","journal-title":"Indian J Med Microbiol"},{"key":"3913_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29","journal-title":"BMJ"},{"issue":"3","key":"3913_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/hdi.12003","volume":"17","author":"P Brown","year":"2013","unstructured":"Brown P, Jay R, Fox A, Oliver M (2013) Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type <scp>II<\/scp> and extracorporeal circuit thrombosis\u2014a case report and review of the literature. Hemodial Int 17(3):444\u2013449","journal-title":"Hemodial Int"},{"key":"3913_CR26","doi-asserted-by":"crossref","unstructured":"Mahieu E, Claes K, Jacquemin M, Evenepoel P, Op De Beek K, Bogaert A, et al. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin\u2010induced thrombocytopenia: dose\u2010finding study and safety evaluation. Artif Organs. 2013 May 5;37(5):482\u20137.","DOI":"10.1111\/aor.12002"},{"issue":"1","key":"3913_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.htct.2020.05.008","volume":"44","author":"EA Osawa","year":"2022","unstructured":"Osawa EA, Brand\u00e3o AAGS, Dias Am\u00e9rico A, Maciel AT (2022) Fondaparinux for systemic anticoagulation during continuous hemofiltration in a patient with heparin-induced thrombocytopenia and limb ischemia - a case report. Hematol Transfus Cell Ther 44(1):108\u2013111","journal-title":"Hematol Transfus Cell Ther"},{"issue":"11\u201312","key":"3913_CR28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2298\/SARH1612654K","volume":"144","author":"J Kusic","year":"2016","unstructured":"Kusic J, Kulic A, Djurkovic V, Markovic R, Milacic V, Suric-Lambic L et al (2016) Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis. Srp Arh Celok Lek 144(11\u201312):654\u2013656","journal-title":"Srp Arh Celok Lek"},{"issue":"13","key":"3913_CR29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.2146\/ajhp090394","volume":"67","author":"JJ Wellborn-Kim","year":"2010","unstructured":"Wellborn-Kim JJ, Mitchell GA, Terneus WF, Stowe CL, Malias MA, Sparkman GM et al (2010) Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. Am J Health-Syst Pharm 67(13):1075\u20131079","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"3913_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5262\/tndt.2010.1001.09","volume":"19","author":"H Taskapan","year":"2010","unstructured":"Taskapan H, Karahan D, Kuku I, Koc S (2010) Heparin-induced thrombocytopenia as a cause of deep venous thrombosis: effectiveness of fondaparinux in dialysis patients. Turk Nephrol Dial Transplant 19(1):55\u201357","journal-title":"Turk Nephrol Dial Transplant"},{"issue":"2","key":"3913_CR31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1542-4758.2012.00710.x","volume":"17","author":"Y Solak","year":"2013","unstructured":"Solak Y, Demircioglu S, Polat I, Biyik Z, Gaipov A, Acar K et al (2013) Heparin-induced thrombocytopenia in a hemodialysis patient treated with fondaparinux: nephrologists between two fires. Hemodial Int 17(2):320\u2013323","journal-title":"Hemodial Int"},{"issue":"6","key":"3913_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4103\/ijn.ijn_194_22","volume":"33","author":"Y Sivaprakasam","year":"2023","unstructured":"Sivaprakasam Y, Chadha S, Kotwal J, Gupta A, Tiwari V, Bhargava V et al (2023) Heparin-induced thrombocytopenia in hemodialysis patients- the first study from India. Indian J Nephrol 33(6):459\u2013463","journal-title":"Indian J Nephrol"},{"issue":"2","key":"3913_CR33","first-page":"166","volume":"26","author":"E Tekg\u00fcnd\u00fcz","year":"2009","unstructured":"Tekg\u00fcnd\u00fcz E, Akpinar S, \u00d6zt\u00fcrk E, Emel Pamuk G, Turgut B, Demir M (2009) Is fondaparinux an effective alternative anticoagulant in patients with heparin-induced thrombocytopenia type II? A case report and review of the literature. Trakya Univ Tip Fak Derg 26(2):166\u2013172","journal-title":"Trakya Univ Tip Fak Derg"},{"issue":"7","key":"3913_CR34","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.nephro.2010.06.001","volume":"6","author":"R Montagnac","year":"2010","unstructured":"Montagnac R, Brahimi S, Janian P, Melin JP, Bertocchio JP, Wynckel A (2010) Int\u00e9r\u00eat du fondaparinux (Arixtra\u00ae) en h\u00e9modialyse dans les thrombop\u00e9nies induites par l\u2019h\u00e9parine de type II (TIH II). \u00c0 propos d\u2019une nouvelle observation. Nephrol Ther 6(7):581\u2013584","journal-title":"Nephrol Ther"},{"issue":"Suppl 2","key":"3913_CR35","first-page":"68","volume":"66","author":"BB Gavrani\u0107","year":"2012","unstructured":"Gavrani\u0107 BB, Basi\u0107-Juki\u0107 N, Kes P (2012) Patient who developed heparin-induced thrombocytopenia type II after 24 years on hemodialysis. Acta Med Croat 66(Suppl 2):68\u201371","journal-title":"Acta Med Croat"},{"issue":"5","key":"3913_CR36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/1744-9987.12699","volume":"22","author":"M Sain","year":"2018","unstructured":"Sain M, Burilovic V, Tomicic M, Jelicic I (2018) High ANTI-PF4\/heparin antibodies titer and thromboses due to infection 9 months after cessation of heparin in hemodialyzed patient with heparin-induced thrombocytopenia. Ther Apher Dial 22(5):558\u2013559","journal-title":"Ther Apher Dial"},{"issue":"1","key":"3913_CR37","first-page":"23","volume":"30","author":"M Fern\u00e1ndez","year":"2010","unstructured":"Fern\u00e1ndez M, Serra D, Rossi L, Bedini Rocca M, Medina Ayala A, Crucelegui S et al (2010) Trombocitopenia inducida por heparina. Revista de nefrolog\u00eda, di\u00e1lisis y transplante 30(1):23\u201328","journal-title":"Revista de nefrolog\u00eda, di\u00e1lisis y transplante"},{"issue":"3","key":"3913_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1053\/j.ajkd.2012.09.015","volume":"61","author":"G Ho","year":"2013","unstructured":"Ho G, Leblanc K, Selby R, Richardson R, Hladunewich M, Battistella M (2013) Use of fondaparinux for circuit patency in hemodialysis patients. Am J Kidney Dis 61(3):525\u2013526","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3913_CR39","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.5830\/CVJA-2015-001","volume":"26","author":"Y Nazli","year":"2015","unstructured":"Nazli Y, Colak N, Demircelik B, Alpay MF, Cakir O, Cagli K (2015) A fatal complication after repair of post-infarction ventricular septal rupture: heparin-induced thrombocytopenia with thrombosis. Cardiovasc J Afr 26(3):e11\u2013e15","journal-title":"Cardiovasc J Afr"},{"issue":"4","key":"3913_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.jvca.2013.09.008","volume":"28","author":"V Cegarra-Sanmart\u00edn","year":"2014","unstructured":"Cegarra-Sanmart\u00edn V, Gonz\u00e1lez-Rodr\u00edguez R, Paniagua-Iglesias P, Santamar\u00eda-Ortiz A, Cueva LF, Gal\u00e1n-Serrano J et al (2014) Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. J Cardiothorac Vasc Anesth 28(4):1008\u20131012","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"4","key":"3913_CR41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1182\/bloodadvances.2019001414","volume":"4","author":"L Skeith","year":"2020","unstructured":"Skeith L, Baumann Kreuziger L, Crowther MA, Warkentin TE (2020) A practical approach to evaluating postoperative thrombocytopenia. Blood Adv 4(4):776\u2013783","journal-title":"Blood Adv"},{"key":"3913_CR42","doi-asserted-by":"crossref","unstructured":"Grouzi E. Update on argatroban for the prophylaxis and treatment of heparin-induced thrombocytopenia type II. J Blood Med. 2014 Aug;131.","DOI":"10.2147\/JBM.S38762"},{"issue":"2","key":"3913_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1751143715618683","volume":"17","author":"C Wall","year":"2016","unstructured":"Wall C, Moore J, Thachil J (2016) Catheter-related thrombosis: a practical approach. J Intensive Care Soc 17(2):160\u2013167","journal-title":"J Intensive Care Soc"},{"issue":"9","key":"3913_CR44","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/ndt\/5.9.802","volume":"5","author":"F Keller","year":"1990","unstructured":"Keller F, Seemann J, Preuschof L, Offermann G (1990) Risk factors of system clotting in heparin-free haemodialysis. Nephrol Dial Transplant 5(9):802\u2013807","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"3913_CR45","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ekir.2022.08.007","volume":"7","author":"J Piotte","year":"2022","unstructured":"Piotte J, Louis F, Buyansky D, Mereniuk E, L\u00e9vesque R, Wald R et al (2022) Online hemodiafiltration compared to conventional hemodialysis in critically ill patients. Kidney Int Rep 7(11):2376\u20132387","journal-title":"Kidney Int Rep"},{"issue":"12","key":"3913_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1160\/TH07-07-0444","volume":"98","author":"R Kalicki","year":"2007","unstructured":"Kalicki R, Aregger F, Alberio L, L\u00e4mmle B, Frey F, Uehlinger D (2007) Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thromb Haemost 98(12):1200\u20131207","journal-title":"Thromb Haemost"},{"key":"3913_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1112770","author":"J Rychl\u00ed\u010dkov\u00e1","year":"2023","unstructured":"Rychl\u00ed\u010dkov\u00e1 J, \u0160r\u00e1mek V, Suk P (2023) Use of fondaparinux in patients with heparin-induced thrombocytopenia on veno-venous extracorporeal membrane oxygenation: a three-patient case series report. Front Med. https:\/\/doi.org\/10.3389\/fmed.2023.1112770","journal-title":"Front Med"},{"issue":"4","key":"3913_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5414\/CPP46198","volume":"46","author":"KI Sombolos","year":"2008","unstructured":"Sombolos KI, Fragia TK, Gionanlis LC, Veneti PE, Bamichas GI, Fragidis SK et al (2008A) Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int J Clin Pharmacol Ther 46(4):198\u2013203","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"3913_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00228-021-03201-1","volume":"78","author":"D Michali\u010dkov\u00e1","year":"2022","unstructured":"Michali\u010dkov\u00e1 D, Hartinger JM, Hladinov\u00e1 Z, Bedn\u00e1\u0159ov\u00e1 V, Szonowsk\u00e1 B, Polakovi\u010d V et al (2022) Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol 78(1):89\u201398","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3913_CR50","doi-asserted-by":"publisher","first-page":"18083","DOI":"10.1038\/s41598-025-03365-1","volume":"15","author":"A Aszkie\u0142owicz","year":"2025","unstructured":"Aszkie\u0142owicz A, Steckiewicz KP, Owczuk R (2025M 24) Evaluating the impact of continuous venovenous hemodiafiltration on the efficacy of prophylactic fondaparinux doses: a prospective single-center observational study. Sci Rep 15(1):18083","journal-title":"Sci Rep"},{"issue":"4","key":"3913_CR51","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A (2012A 7) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120(4):c179\u2013c184","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"3913_CR52","first-page":"105","volume":"1","author":"A Koster","year":"2007","unstructured":"Koster A, Fischer KG, Harder S, Mertzlufft F (2007) The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT. Biologics 1(2):105\u2013112","journal-title":"Biologics"},{"issue":"6","key":"3913_CR53","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.athoracsur.2003.09.034","volume":"76","author":"TE Warkentin","year":"2003","unstructured":"Warkentin TE, Greinacher A (2003) Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 76(6):2121\u20132131","journal-title":"Ann Thorac Surg"},{"key":"3913_CR54","doi-asserted-by":"crossref","unstructured":"Barali\u0107 M, Gligorijevi\u0107 N, Brkovi\u0107 V, Katrl\u00edk J, Pa\u017eitn\u00e1 L, \u0160underi\u0107 M, et al. Fibrinogen fucosylation as a prognostic marker of end-stage renal disease in patients on peritoneal dialysis. Biomolecules. 2020 Aug 9;10(8).","DOI":"10.3390\/biom10081165"},{"issue":"31\u201332","key":"3913_CR55","first-page":"525","volume":"110","author":"A Schlitt","year":"2013","unstructured":"Schlitt A, J\u00e1mbor C, Spannagl M, Gogarten W, Schilling T, Zwissler B (2013) The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. Dtsch Arztebl Int 110(31\u201332):525\u2013532","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"3913_CR56","volume":"12","author":"AH Siddiqui","year":"2020","unstructured":"Siddiqui AH, Ahmed M, Khan TMA, Abbasi S, Habib S, Khan HM et al (2020M 8) Trends and outcomes of gastrointestinal bleeding among septic shock patients of the United States: a 10-year analysis of a nationwide inpatient sample. Cureus 12(5)","journal-title":"Cureus"},{"issue":"77","key":"3913_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","volume":"20","author":"SI Blot","year":"2014","unstructured":"Blot SI, Pea F, Lipman J (2014) The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2013concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 20(77):3\u201311","journal-title":"Adv Drug Deliv Rev"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03913-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03913-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03913-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:01:51Z","timestamp":1764914511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03913-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3913"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03913-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this systematic review because the study involved analysis of previously published data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not required for this systematic review, as it involved analysis of anonymized data obtained from previously published studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}